Skip to main content
. Author manuscript; available in PMC: 2013 Apr 15.
Published in final edited form as: Clin Cancer Res. 2012 Jan 27;18(8):2309–2315. doi: 10.1158/1078-0432.CCR-11-1815

Table 1b.

Summary of results from the patients included in the analyses from the phase III trial of AE 941 vs. placebo.

AE 941 arm (n = 131) Placebo arm (n = 128)
Mean ± SD number of target lesions used 2.3 ± 0.8 2.3 ± 0.8
Mean ± SD baseline tumor size (mm) 97.1 ± 57.6 104.1 ± 58.9
RR by RECIST at 8 weeks 2.3 % 0.8%
Mean ± SD % change in tumor size at 8 weeks vs. baseline 13.0% ± 27.9% 16.2% ± 22.1%
Mean log ratio ± SD of tumor size at 8 weeks vs. baseline 0.10 ± 0.22 0.13 ± 0.18